MIRA 8-K
Mira Pharmaceuticals, Inc. (MIRA)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State
or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS
Employer Identification No.) |
(Address of Principal Executive Offices)
Registrant’s
telephone number, including area code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
On May 6, 2025, MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced the completion of a regulatory-required neurotoxicity study of Ketamir-2, the Company’s novel oral NMDA receptor antagonist. The study was conducted in accordance with FDA guidance as part of the Company’s ongoing clinical development program.
The study evaluated the potential for Ketamir-2 to produce neuropathologic changes, including Olney lesions, which have historically been associated with certain NMDA receptor antagonists such as ketamine and MK-801. The study was conducted in sexually mature Sprague-Dawley rats. Animals were administered high oral doses of Ketamir-2, while a separate positive control group received MK-801. All animals were observed for clinical signs and underwent detailed histopathological brain analysis at two timepoints.
Key findings from the study include:
| ● | No test article-related mortality or adverse clinical signs were observed in animals treated with Ketamir-2. | |
| ● | No microscopic or macroscopic brain lesions were detected in Ketamir-2-treated groups. | |
| ● | Positive control animals treated with MK-801 showed clear evidence of vacuolation and neuronal necrosis, consistent with Olney-type lesions. |
The results of the study indicate that Ketamir-2 did not induce neurotoxic changes under the study conditions.
These findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of MIRA’s ongoing regulatory communications.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MIRA PHARMACEUTICALS, INC. | ||
| Dated: May 6, 2025 | By: | /s/ Erez Aminov |
| Name: | Erez Aminov | |
| Title: | Chief Executive Officer | |